Dr. Venkataraman Sriram (Sriram) is the Chief Scientific Officer at Foundery Innovations, Inc. Sriram has over 15 years of biopharmaceutical research experience developing biological and small molecule therapeutics against immunotherapy targets. Prior to starting Foundery, Sriram was at Pionyr Immunotherapeutics from the early stages. Before getting bit by the start-up bug, Sriram was at Gilead Sciences for close to three years. Sriram established and successively led several immuno-oncology programs at Gilead Sciences and previously at Merck. At Merck Research Laboratories (formerly the Schering-Plough Biopharma prior to its acquisition by Merck), Sriram also served as the cross-site pharmacology lead for all immuno-oncology programs, including the anti-PD-1 antibody Keytruda. Sriram received his Ph.D. degree in Biochemistry and Immunology from the University of Madras, India, and completed his post-doctoral training in immunology at the Indiana University School of Medicine.